1. Home
  2. SPRO vs ACNT Comparison

SPRO vs ACNT Comparison

Compare SPRO & ACNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • ACNT
  • Stock Information
  • Founded
  • SPRO 2013
  • ACNT 1945
  • Country
  • SPRO United States
  • ACNT United States
  • Employees
  • SPRO N/A
  • ACNT N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • ACNT Steel/Iron Ore
  • Sector
  • SPRO Health Care
  • ACNT Industrials
  • Exchange
  • SPRO Nasdaq
  • ACNT Nasdaq
  • Market Cap
  • SPRO 121.0M
  • ACNT 122.5M
  • IPO Year
  • SPRO 2017
  • ACNT N/A
  • Fundamental
  • Price
  • SPRO $1.90
  • ACNT $12.65
  • Analyst Decision
  • SPRO Buy
  • ACNT
  • Analyst Count
  • SPRO 4
  • ACNT 0
  • Target Price
  • SPRO $5.00
  • ACNT N/A
  • AVG Volume (30 Days)
  • SPRO 391.2K
  • ACNT 61.8K
  • Earning Date
  • SPRO 08-12-2025
  • ACNT 11-11-2025
  • Dividend Yield
  • SPRO N/A
  • ACNT N/A
  • EPS Growth
  • SPRO N/A
  • ACNT N/A
  • EPS
  • SPRO N/A
  • ACNT N/A
  • Revenue
  • SPRO $48,576,000.00
  • ACNT $172,594,000.00
  • Revenue This Year
  • SPRO N/A
  • ACNT $22.72
  • Revenue Next Year
  • SPRO N/A
  • ACNT N/A
  • P/E Ratio
  • SPRO N/A
  • ACNT N/A
  • Revenue Growth
  • SPRO N/A
  • ACNT 33.04
  • 52 Week Low
  • SPRO $0.51
  • ACNT $8.16
  • 52 Week High
  • SPRO $3.22
  • ACNT $13.70
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 39.50
  • ACNT 57.24
  • Support Level
  • SPRO $1.91
  • ACNT $12.03
  • Resistance Level
  • SPRO $2.18
  • ACNT $12.69
  • Average True Range (ATR)
  • SPRO 0.10
  • ACNT 0.37
  • MACD
  • SPRO 0.01
  • ACNT 0.07
  • Stochastic Oscillator
  • SPRO 19.18
  • ACNT 92.86

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About ACNT Ascent Industries Co.

Ascent Industries Co is engaged in the chemical and metal industry. The group operates into two reportable segments namely the Specialty Chemicals and Tubular Products. The Tubular Products segment serves markets through pipe and tube and customers in the appliance, architectural, automotive, and commercial transportation, brewery, chemical, petrochemical, and other industries. The Specialty Chemicals segment produces specialty products for pulp and paper, coatings, adhesives, sealants, and elastomers (CASE), textile, automotive, household, and other industries. It manufactures welded pipe and tube, majorly from stainless steel, duplex, and nickel alloys. The company also produces specialty chemicals and dyes used in various end markets.

Share on Social Networks: